Dual antiangiogenic therapy using lenalidomide and bevacizumab with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
Year: 2012
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Bamidele Adesunloye, Xuan Huang, Yangmin M. Ning, Ravi A. Madan, James L. Gulley, Melony Beatson, Paul Gustav Kluetz, David E. Adelberg, Philip M. Arlen, Howard L. Parnes, Marcia Mulquin, Seth M. Steinberg, John Joseph Wright, Jane B. Trepel, Nancy Ann Dawson, Clara Chen, Carol Bassim, Andrea Borghese Apolo, William Douglas Figg, William L. Dahut
Institutions: National Institutes of Health, National Cancer Institute, United States Food and Drug Administration, Center for Cancer Research, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, National Institutes of Health Clinical Center, National Institute of Dental and Craniofacial Research
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2966433369